- Home
- SMBK vs KROS Comparison
SMBK vs KROS Comparison
Compare SMBK & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMBK
- KROS
- Stock Information
- Founded
- SMBK N/A
- KROS 2015
- Country
- SMBK United States
- KROS United States
- Employees
- SMBK N/A
- KROS N/A
- Industry
- SMBK Major Banks
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- SMBK Finance
- KROS Health Care
- Exchange
- SMBK Nasdaq
- KROS Nasdaq
- Market Cap
- SMBK 534.5M
- KROS 460.6M
- IPO Year
- SMBK N/A
- KROS 2020
- Fundamental
- Price
- SMBK $35.32
- KROS $11.00
- Analyst Decision
- SMBK Buy
- KROS Buy
- Analyst Count
- SMBK 6
- KROS 11
- Target Price
- SMBK $30.50
- KROS $45.33
- AVG Volume (30 Days)
- SMBK 55.9K
- KROS 2.1M
- Earning Date
- SMBK 01-21-2025
- KROS 02-26-2025
- Dividend Yield
- SMBK 0.91%
- KROS N/A
- EPS Growth
- SMBK 26.63
- KROS N/A
- EPS
- SMBK 2.14
- KROS N/A
- Revenue
- SMBK $166,349,000.00
- KROS $651,000.00
- Revenue This Year
- SMBK N/A
- KROS $303.27
- Revenue Next Year
- SMBK $9.70
- KROS N/A
- P/E Ratio
- SMBK $16.24
- KROS N/A
- Revenue Growth
- SMBK 11.36
- KROS 8037.50
- 52 Week Low
- SMBK $19.00
- KROS $9.78
- 52 Week High
- SMBK $37.72
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- SMBK 61.57
- KROS 24.79
- Support Level
- SMBK $34.88
- KROS $11.04
- Resistance Level
- SMBK $35.87
- KROS $11.99
- Average True Range (ATR)
- SMBK 0.86
- KROS 0.60
- MACD
- SMBK 0.36
- KROS 1.20
- Stochastic Oscillator
- SMBK 77.62
- KROS 43.99
About SMBK SmartFinancial Inc.
SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.